**Question:** Which one of the following is not an intravesical chemotherapeutic agent?

A. Mitomycin C
B. Bacillus Calmette-Guérin (BCG)
C. Thiotepa
D. Hydrogen peroxide

**Core Concept:** Intravesical chemotherapy is the administration of chemotherapy drugs directly into the bladder to treat bladder cancer or other bladder diseases. The drugs are retained within the bladder for a specific period before being eliminated from the body. The correct options are those that are not used for intravesical therapy.

**Why the Correct Answer is Right:**

**Option D (Hydrogen peroxide):** Hydrogen peroxide is a strong oxidizing agent and disinfectant, not specifically used as an intravesical chemotherapeutic agent. While it may have some potential cytotoxic effects on bladder cells, it is not a targeted therapy for bladder cancer or other bladder diseases.

**Why Each Wrong Option is Incorrect:**

**Option A (Mitomycin C):** Mitomycin C is a chemotherapeutic agent used for intravesical therapy in the treatment of bladder cancer and non-muscle-invasive bladder tumors. It works by inhibiting DNA synthesis and is a targeted therapy for bladder cancer management.

**Option B (Bacillus Calmette-Guérin, BCG):** Bacillus Calmette-Guérin is a live attenuated strain of Mycobacterium bovis that is used as an immunotherapy for non-muscle-invasive bladder cancer. It stimulates the immune system to target cancer cells, making it a specific intravesical therapy for bladder cancer.

**Option C (Thiotepa):** Thiotepa is a cytotoxic chemotherapeutic agent used for intravesical therapy in the treatment of non-muscle-invasive bladder cancer. It inhibits DNA synthesis, similar to Mitomycin C, making it a targeted therapy for bladder cancer management.

**Correct Answer Explanation:**

**Option D (Hydrogen peroxide) is not an intravesical chemotherapeutic agent.** It is a disinfectant and oxidizing agent, not specifically designed for treating bladder cancer or other bladder diseases. Mitomycin C, BCG, and Thiotepa are cytotoxic agents used for intravesical therapy in the management of non-muscle-invasive bladder cancer, targeting cancer cells via inhibition of DNA synthesis.

**Clinical Pearl:** Intravesical therapy plays a crucial role in the treatment of non-muscle-invasive bladder cancer. It targets cancer cells specifically, minimizing systemic side effects. Cytotoxic agents like Mitomycin C, BCG, and Thiotepa are administered directly into the bladder to eliminate cancer cells while sparing normal bladder cells.